Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals to $384 from $342 and keeps an Overweight rating on the shares post the Q1 results. The analyst continues to see the company’s cystic fibrosis franchise supporting a "floor value" with its pipeline assets providing additional upside. The firm notes that Vertex has multiple pipeline updates in 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex Pharmaceuticals reports Q1 EPS $2.69, consensus $3.00
- Vertex options imply 3.8% move in share price post-earnings
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex announces U.S. FDA approval for expanded use of Trikafta
- Stablix, Vertex collaborate for targeted protein stabilization therapeutics